-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of October 27, Yiling Pharmaceutical released its third quarterly report, and in the third quarter of 2022, the company achieved operating income of 2.
380 billion yuan, a year-on-year increase of 7.
41%; The net profit attributable to the shareholders of the listed company was 366 million yuan, a year-on-year increase of 40.
92%; The net profit of non-attributable parent was 365 million yuan, a year-on-year increase of 49.
32%.
In the first three quarters, the R&D expense of Yiling Pharmaceutical was 552 million yuan, and the R&D expense ratio increased by 2.
6%
year-on-year.
380 billion yuan, a year-on-year increase of 7.
41%; The net profit attributable to the shareholders of the listed company was 366 million yuan, a year-on-year increase of 40.
92%; The net profit of non-attributable parent was 365 million yuan, a year-on-year increase of 49.
32%.
In the first three quarters, the R&D expense of Yiling Pharmaceutical was 552 million yuan, and the R&D expense ratio increased by 2.
6%
year-on-year.
According to public information, the company's R&D investment in 2016~2021 was 240 million yuan, 260 million yuan, 360 million yuan, 520 million yuan, 740 million yuan and 838 million yuan respectively, and the proportion of R&D investment in operating income exceeded 8% for four consecutive years, ranking the leading level
in the same industry.
in the same industry.
Continuous high R&D investment makes the transformation of Chinese medicine achievements full
of confidence.
Under the guidance of network disease theory, Yiling Pharmaceutical has developed 13 innovative patented traditional Chinese medicines, covering diseases with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and so on
.
At present, the medication of cardiovascular and cerebrovascular diseases and respiratory diseases has been in the leading position
in the industry.
of confidence.
Under the guidance of network disease theory, Yiling Pharmaceutical has developed 13 innovative patented traditional Chinese medicines, covering diseases with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, nervous system diseases, urinary system diseases and so on
.
At present, the medication of cardiovascular and cerebrovascular diseases and respiratory diseases has been in the leading position
in the industry.
Focusing on the research and development of traditional Chinese medicines, Yiling Pharmaceutical focuses on core therapeutic areas such as cardiovascular and cerebrovascular, respiratory, nervous, endocrine, digestive, immunological, urinary, and oncology, creating an innovative Chinese medicine evidence chain of "three combinations" of traditional Chinese medicine theory, human experience, and clinical trials, and practicing a new model
of innovation and transformation of traditional Chinese medicine that integrates "theory + clinical + new drug + experiment + evidence-based".
of innovation and transformation of traditional Chinese medicine that integrates "theory + clinical + new drug + experiment + evidence-based".
The varieties under research cover diseases of the cardiovascular system, respiratory system, endocrine and metabolic system, nervous system, digestive system, gynecology, pediatrics and other diseases, which are in different stages
of new drug research and development.
At present, Qihuang Mingmu Capsule for the treatment of diabetic retinopathy is applying for new drugs, and the Phase II clinical study of new drugs has been completed, and phase III clinical research is being carried out.
The treatment of children's colds has completed phase II.
clinical outlets.
Chai Qintong Tablets obtained the approval notice
for clinical trials of drugs with new indications of "recurrent urinary tract infections".
of new drug research and development.
At present, Qihuang Mingmu Capsule for the treatment of diabetic retinopathy is applying for new drugs, and the Phase II clinical study of new drugs has been completed, and phase III clinical research is being carried out.
The treatment of children's colds has completed phase II.
clinical outlets.
Chai Qintong Tablets obtained the approval notice
for clinical trials of drugs with new indications of "recurrent urinary tract infections".
It is reported that since 2000, the innovative Chinese medicine developed under the guidance of network disease theory and its guidance has won six national science and technology awards
.
Among them, in January 2020, the project "Construction of Traditional Chinese Medicine Context Theory and Its Guidance for the Prevention and Treatment of Microangiolesion" won the first prize of the 2019 National Science and Technology Progress Award, which is also the only first prize in the field of medicine and health in China
.
The award proves the clinical efficacy of Tongxinluo capsules, Sansong Yangxin capsules, Qiqiang Qiangxin capsules and other Tongxin drugs in cardiovascular and cerebrovascular diseases, and also explains the charm
of combining traditional Chinese medicine with modern technology.
The six awards cover theoretical innovation, technological invention and applied research, which is a microcosm of the transformation of traditional Chinese medicine innovation achievements of Yiling Pharmaceutical and an effective "bargaining chip"
for Yiling Pharmaceutical's continuous innovation.
.
Among them, in January 2020, the project "Construction of Traditional Chinese Medicine Context Theory and Its Guidance for the Prevention and Treatment of Microangiolesion" won the first prize of the 2019 National Science and Technology Progress Award, which is also the only first prize in the field of medicine and health in China
.
The award proves the clinical efficacy of Tongxinluo capsules, Sansong Yangxin capsules, Qiqiang Qiangxin capsules and other Tongxin drugs in cardiovascular and cerebrovascular diseases, and also explains the charm
of combining traditional Chinese medicine with modern technology.
The six awards cover theoretical innovation, technological invention and applied research, which is a microcosm of the transformation of traditional Chinese medicine innovation achievements of Yiling Pharmaceutical and an effective "bargaining chip"
for Yiling Pharmaceutical's continuous innovation.
